BROOKLYN

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Underlying HeFH and/or ASCVD and LDL-C >100 mg/dL Who are Not Adequately Controlled by Their Lipid-Modifying Therapies